Article
Hepatic steatosis in patients with chronic hepatitis C virus genotype 2 or 3 does not affect viral response in patients treated with peginterferon alpha-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) for 16 or 24 weeks.
Liver international : official journal of the International Association for the Study of the Liver - 1 Feb 2009
Rodriguez-Torres Maribel, Govindarajan Sugantha, Diago Moises, Morgan Thomas, Anand Bhupinderjit, Barange Karl, Suter Frank, Lin Amy, Hooper Gregory, Shiffman Mitchell
Abstract excerpt
BACKGROUND: Hepatic steatosis is common in patients infected with hepatitis C virus (HCV). The effect of steatosis on anti-HCV therapy efficacy is unclear. METHODS: We studied host and viral factors associated with steatosis and the effect of steatosis on treatment efficacy using the database of a large prospective trial in patients with HCV genotypes 2 and 3. RESULTS: Out of 885 patients assessed for steatosis,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.